Multiple tumor-associated antigens recognized via native T-cell receptor and Natural Killer cell receptors (Multi-TAA)

Multiple tumor-associated antigens (Multi-TAAs) represent a therapeutic strategy rather than a single molecular entity, focusing on a broad profile of proteins overexpressed in malignant cells such as PRAME, WT1, Survivin, and NY-ESO-1. By targeting several antigens simultaneously through native T-cell receptors (TCRs) and Natural Killer (NK) cell receptors, this approach aims to overcome the limitations of single-antigen targeting, such as tumor escape through antigen loss or downregulation. These antigens are typically involved in essential cellular processes like cell cycle regulation and apoptosis inhibition, making them ideal targets for immunotherapy. In clinical applications, patient-derived or donor-derived immune cells are expanded to recognize these specific antigen signatures, providing a polyfunctional attack against both hematologic malignancies and solid tumors. This multi-pronged recognition enhances the durability of the immune response and minimizes the risk of relapse compared to monovalent therapies.

Other names

Multi-tumor associated antigensMulti-TAA-specific T cellsTumor-associated antigensTAA

Adoptive transfer of T cells or NK cells expanded ex vivo to recognize a specific profile of multiple tumor-associated antigens through their native receptors, inducing polyfunctional immune responses and reducing the risk of tumor escape via antigen loss.